The Zhitong Finance App learned that the globalization of innovative drugs is changing from a narrative that has been told for many years to figures that can be checked on profit statements. On October 27, Fosun Pharmaceutical, a core subsidiary of Fosun International (00656.HK) health sector, announced results for the first three quarters of 2026: operating income of 30.463 billion yuan, up 3.64% year on year; net profit to mother of 2,667 billion yuan, up 5.71% year on year; net profit after deducting non-return to mother was 1,706 billion yuan, up 8.42% year on year. Profits are faster than revenue, and the core driving force is “continuous growth in revenue from innovative drugs and steady improvement in operating efficiency”.

The Zhitong Finance App learned that the globalization of innovative drugs is changing from a narrative that has been told for many years to figures that can be checked on profit statements. On October 27, Fosun Pharmaceutical, a core subsidiary of Fosun International (00656.HK) health sector, announced results for the first three quarters of 2026: operating income of 30.463 billion yuan, up 3.64% year on year; net profit to mother of 2,667 billion yuan, up 5.71% year on year; net profit after deducting non-return to mother was 1,706 billion yuan, up 8.42% year on year. Profits are faster than revenue, and the core driving force is “continuous growth in revenue from innovative drugs and steady improvement in operating efficiency”.